GlaxoSmithKline Acquires Okairos for $325 Million

England-based GlaxoSmithKline (NYSE: GSK  ) has acquired Switzerland-based biopharmaceutical firm Okairos, a specialist in developing proprietary technologies and genetic vaccines to treat infectious diseases including malaria, hepatitis C, HIV, and cancer, GlaxoSmithKline announced today.

The deal calls for GlaxoSmithKline to pay $325 million in cash for a 100% ownership stake of Okairos, including its platform technology utilizing viral vectors to stimulate immune responses, and a "small number of early stage assets," according to the company's press release.

The proprietary technology Okairos has developed is expected to complement existing Glaxo systems, and will play a key role in the development of new therapeutic vaccines for the treatment of diseases and infections. Christophe Weber, president GlaxoSmithKline Vaccines, expects the transaction will, "contribute to the development efforts for an exciting new generation of vaccines, building on the excellent science and expertise of both companies."

The management teams from GlaxoSmithKline and Okairos will work together to ensure a smooth transition, while maintaining Okairos' "autonomy, spirit and agility," GlaxoSmithKline said.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2458524, ~/Articles/ArticleHandler.aspx, 4/19/2014 2:05:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement